

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (AB-68)

BECLABUVIR

PRONUNCIATION

bek la bue' vir


THERAPEUTIC CLAIM

Treatment of hepatitis C infection

CHEMICAL NAMES

1. Cycloprop[*d*]indolo[2,1-*a*][2]benzazepine-9-carboxamide, 12-cyclohexyl-*N*-[(dimethylamino)sulfonyl]-4*b*,5,5*a*,6-tetrahydro-3-methoxy-5*a*-[(3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl]-, (4*bS*,5*aR*)-
2. (4*bS*,5*aR*)-12-cyclohexyl-*N*-(dimethylsulfamoyl)-3-methoxy-5*a*-[(3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl]-4*b*,5,5*a*,6-tetrahydrocyclopropa[*d*]indolo[2,1-*a*][2]benzazepine-9-carboxamide

STRUCTURAL FORMULA



MOLECULAR FORMULA

 $C_{36}H_{45}N_5O_5S$

MOLECULAR WEIGHT

659.8

TRADEMARK

None as yet

SPONSOR

Bristol-Myers Squibb Company

CODE DESIGNATIONS

BMS-791325

CAS REGISTRY NUMBER

958002-33-0

WHO NUMBER

9899

SCS